Abdi Ibrahim Pharmaceuticals, the leader in the Turkish pharmaceutical industry for 21 years, continues its unwavering commitment to investing in biotechnology.
Abdi İbrahim has announced a technology transfer agreement with the Spanish biosimilar developer, which is among the world’s leading companies in the field. Accordingly, a currently imported cancer drug will now be manufactured by AbdiBio.
The technology transfer will enable the production of a drug used in the treatment of metastatic colorectal cancer and cervical cancer as well as the most common and difficult-to-treat type of brain tumour, glioblastoma multiforme. This is unprecedented in Türkiye’s biotechnology sector, as it involves the entire process from “cell-to-end product.” In other words, the production of the monoclonal antibody (mab), is a pioneering achievement in biotechnology for Türkiye.
Nezih Barut, Chairman of Abdi İbrahim, noted the technology transfer’s significance as the first “cell-to-end product” biotech pharmaceutical in Türkiye. Barut said; “With AbdiBio, the largest biotech pharmaceutical manufacturing facility in Türkiye, our goal is to make our mark in local and international markets alike. With this agreement, Abdi İbrahim’s ambition to become a leader in the biotechnology field takes a critical step forward, as we will now be able to locally produce from the cellular level (Drug Substance) a cancer drug that Türkiye has previously been importing.”
Barut, emphasized the significance of this agreement by stating, “Our licensing partnership with mAbxience, a company whose products are used in over 100 countries worldwide, has been ongoing since 2012. The most critical phase in biotechnology products is the process of obtaining protein from cells. With this technology transfer, we will be manufacturing the protein ourselves, thus localizing every phase of a biotechnology drug.”
Jurgen Van Broeck, Global Commercial Director of mAbxience, claimed, “mAbxience’s expertise in CDMO and its comprehensive capabilities, including cell line development, process development, and large-scale manufacturing, play a crucial role in this partnership. With GMP-approved facilities in Europe and South America, mAbxience is at the forefront of delivering integrated biomanufacturing solutions globally. We are excited to bring this level of innovation and self-sufficiency in biopharmaceuticals to Türkiye. This agreement is not just about technology transfer; it’s about shaping the future of global healthcare.”
👉The first biotech pharmaceutical to be locally manufactured in Türkiye will bear the mark of AbdiBio from the cellular level – Press Releases | Abdi İbrahim (abdiibrahim.com.tr)
